Selective Differential Exploitation (SDE) is a methodology for eliminating a target while preserving the protected within a shared environment. Any two distinguishable sets will exhibit measurable differences. Near binary / binary differentials (present in one set, absent or minimal in the other) can be identified, widened, and exploited (singly where leverage is high, or multiplicatively where many independent mechanisms are available) to achieve selective elimination with high composite precision. The methodology inverts conventional drug discovery: agents are selected last, not first. The starting point is the set of differences between target and protected, the threshold cliffs at which small changes trigger catastrophic collapse, and the condition of the specific patient or system at the moment of intervention. Agents are chosen because they move the target across a cliff while leaving the other untouched or supported. This paper presents the methodology step by step, illustrated with a theorized approach to late-stage KRAS-mutant pancreatic cancer (PDAC) in which an electron transport chain structural differential was selected because exploiting it would simultaneously damage cancer and energize the patient. The approach is presented for validation or refutation.
Andrew Hooks (Thu,) studied this question.